Pfizer’s SWOT analysis: stock navigates patent cliff with new drugs
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Pfizer's stock is navigating a patent cliff, but the company has new drugs in its pipeline. Investors are focusing on the company's earnings and pipeline as it faces this challenge. Goldman Sachs has maintained a neutral rating on Pfizer's stock amid the patent cliff.